Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: A historical review of cytogenetics in the light of todays knowledge

Leukemia

Volumn 23, Issue 2, 2009, Pages 225-234

  Boerma, E G ^a   Siebert, R ^b   Kluin, P M ^a   Baudis, M ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MYC PROTEIN; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL 6; VINCRISTINE;

AGE DISTRIBUTION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER MORPHOLOGY; CHROMOSOME 12; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME 6Q; CHROMOSOME 7; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 3; CHROMOSOME TRANSLOCATION 8; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KARYOTYPING; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 60149087553     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.281     Document Type: Review

References (59)

1. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46: 218-223.
2. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 702-703.
3. Kohn G, Mellman WJ, Moorhead PS, Loftus J, Henle G. Involvement of C group chromosomes in five Burkitt lymphoma cell lines. J Natl Cancer Inst 1967; 38: 209-222.
4. Manolov G, Manolova Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 1972; 237: 33-34.
5. Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 1976; 17: 47-56.
6. Berger R, Bernheim A, Weh HJ, Flandrin G, Daniel MT, Brouet JC et al. A new translocation in Burkitt's tumor cells. Hum Genet. 1979; 53: 111-112.
7. Miyoshi I, Hiraki S, Kimura I, Miyamoto K, Sato J. 2/8 translocation in a Japanese Burkitt's lymphoma. Experientia. 1979; 35: 742-743.
8. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7827.
9. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982; 79: 7837-7841.
10. Erikson J, Finan J, Nowell PC, Croce CM. Translocation of immunoglobulin VH genes in Burkitt lymphoma. Proc Natl Acad Sci USA 1982; 79 5611-5615.
11. Malcolm S, Barton P, Murphy C, Ferguson-Smith MA, Bentley DL, Rabbitts TH. Localization of human immunoglobulin kappa light chain variable region genes to the short arm of chromosome 2 by in situ hybridization. Proc Natl Acad Sci USA 1982; 79: 4957-4961.
12. Chapelle de la CA, Lenoir G, Boue J, Boue A, Gallano P, Huerre C et al. Lambda Ig constant region genes are translocated to chromosome 8 in Burkitt's lymphoma with t(8;22). Nucleic Acids Res 1983; 11 1133-1142.
13. Sigaux F, Berger R, Bernheim A, Valensi F, Daniel MT, Flandrin G. Malignant lymphomas with band 8q24 chromosome abnormality: A morphologic continuum extending from Burkitt's to immunoblastic lymphoma. Br J Haematol 1984; 57: 393-405.
14. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt Lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 181-184.
15. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
16. Smeland S, Blystad AK, Kvaloy SO, Ikonomou IM, Delabie J, Kvalheim G et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: A 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15: 1072-1078.
17. Kaiser U, Uebelacker I, Havemann K. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: A report on 58 patients. Leuk Lymphoma 1999; 36: 101-108.
18. Butler RD, Hainsworth JD. Optimal therapy for small noncleaved cell lymphoma. Cancer Treat Res 1993; 66: 65-79.
19. Haralambieva E, Boerma EJ, van Imhoff GW, Rosati S, Schuuring E, Muller-Hermelink HK et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005; 29: 1086-1094.
20. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384-392.
21. Sevilla DW, Gong JZ, Goodman BK, Buckley PJ, Rosoff P, Gockerman JP et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol 2007; 128: 981-991.
22. Chuang SS, Ye H, Du MQ, Lu CL, Dogan A, Hsieh PP et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: A comparative study with EBER and FISH. Am J Clin Pathol 2007; 128: 558-564.
23. Nakamura N, Nakamine H, Tamaru J, Nakamura S, Yoshino T, Ohshima K et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol 2002; 15: 771-776.
24. Braziel RM, Arber DA, Slovak ML, Gulley ML, Spier C, Kjeldsberg C et al. The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001; 97: 3713-3720.
25. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.
26. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442.
27. Berger R, Bernheim A. Cytogenetic studies on Burkitt's lymphoma-leukemia. Cancer Genet Cytogenet 1982; 7: 231-244.
28. Barth TF, Muller S, Pawlita M, Siebert R, Rother JU, Mechtersheimer G et al. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. J Pathol 2004; 203: 940-945.
29. Garcia JL, Hernandez JM, Gutierrez NC, Flores T, Gonzalez D, Calasanz MJ et al. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 2003; 17: 2016-2024.
30. Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M et al. Small noncleaved, non-Burkitt's (Burkit-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999; 17: 1558-1567.
31. Salaverria I, Zettl A, Bea S, Dave SS, Wright GW, Hartmann E et al. Chromosomal alterations detected by comparative genomic hybridization (CGH) in subgroups of gene expression-defined Burkitt lymphoma. Haematologica 2008; 93: 1327-1334.
32. Mitelman Database of Chromosome Aberrations in Cancer. 2008, Mitelman F, Johansson B and Mertens F (eds). http://cgap.nci.nih.gov/Chromosomes/ Mitelman.
33. Gazzo S, Chudoba I, Traverse-Glehen A, Baseggio L, Felman P, Berger F et al. Detailed characterization of 7q deletions by multicolor banding (mBAND) in marginal zone cell lymphoma. Cancer Genet Cytogenet 2007; 175: 159-165.
34. Baudis M, Cleary ML. Progenetix.net: An online repository for molecular cytogenetic aberration data. Bioinformatics 2001; 17: 1228-1229.
35. van de Wiel MA, Smeets SJ, Brakenhoff RH, Ylstra B. CGH MultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics 2005; 21: 3193-3194.
36. Boerma EG, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC. Gender and age-related differences in Burkitt lymphoma - epidemiological and clinical data from The Netherlands. Eur J Cancer 2004; 40: 2781-2787.
37. Han X, Kilfoy B, Zheng T, Holford TR, Zhu C, Zhu Y et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008; 19: 841-858.
38. Levine PH, Connelly RR, McKay FW. Burkitt's lymphoma in the USA: Cases reported to the American Burkitt Lymphoma Registry compared with population-based incidence and mortality data. IARC Sci Publ 1985; 60: 217-224.
39. Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 2008; 112: 1374-1381.
40. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience. Br J Haematol 2003; 120: 660-670.
41. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 2005; 29: 1652-1660.
42. Ladanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RS. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991; 77: 1057-1063.
43. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
44. Akasaka T, Akasaka H, Ueda C, Yonetani N, Maesako Y, Shimizu A et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 2000; 18: 510-518.
45. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992; 80 758-767.
46. Tirier C, Zhang Y, Plendl H, Weber-Matthiesen K, Langer W, Heit W et al. Simultaneous presence of t(11;14) and a variant Burkitt's translocation in the terminal phase of a mantle cell lymphoma. Leukemia 1996; 10: 346-350.
47. Bisiau H, Daudignon A, Le BF, Pollet JP, Preudhomme C, Duthilleul P et al. Transformation of follicular lymphoma with both t(14;18) and t(8;22). Nouv Rev Fr Hematol 1995; 37: 241-244.
48. Davies AJ, Rosenwald A, Wright G, Lee A, Last KW, Weisenburger DD et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136: 286-293.
49. Gauwerky CE, Haluska FG, Tsujimoto Y, Nowell PC, Croce CM. Evolution of B-cell malignancy: Pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene. Proc Natl Acad Sci USA 1988; 85: 8548-8552.
50. Wong KF. Transformed follicular lymphoma with concurrent t(2;3), t(8;14) and t(14;18). Cancer Genet Cytogenet 2007; 173: 68-70.
51. Lacy J, Summers WP, Watson M, Glazer PM, Summers WC. Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. Proc Natl Acad Sci USA 1987; 84: 5838-5842.
52. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I et al. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma 2006; 47: 1885-1893.
53. Bertrand P, Bastard C, Maingonnat C, Jardin F, Maisonneuve C, Courel MN et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia 2007; 21: 515-523.
54. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol 2006; 19: 25-33.
55. Thangavelu M, Olopade O, Beckman E, Vardiman JW, Larson RA, McKeithan TW et al. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer 1990; 2: 147-158.
56. D'Achille P, Seymour JF, Campbell LJ. Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: A study of 12 cases and review of the literature. Cancer Genet Cytogenet 2006; 171: 52-56.
57. Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: A clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma 2004; 45: 519-528.
58. Einerson RR, Law ME, Blair HE, Kurtin PJ, McClure RF, Ketterling RP et al. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. Leukemia 2006; 20: 1790-1799.
59. Joos S, Haluska FG, Falk MH, Henglein B, Hameister H, Croce CM et al. Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc. Cancer Res 1992; 52: 6547-6552.